| 8.27 0.52 (6.71%) | 09-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 9.84 |
1-year : | 11.5 |
| Resists | First : | 8.43 |
Second : | 9.84 |
| Pivot price | 7.75 |
|||
| Supports | First : | 7.7 |
Second : | 7.26 |
| MAs | MA(5) : | 7.76 |
MA(20) : | 7.76 |
| MA(100) : | 7.37 |
MA(250) : | 13.85  |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 57.8 |
D(3) : | 40.5 |
| RSI | RSI(14): 66.3 |
|||
| 52-week | High : | 29.61 | Low : | 5.9 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ARVN ] has closed above the upper band by 16.3%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 50% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 12 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 8.44 - 8.47 | 8.47 - 8.51 |
| Low: | 7.65 - 7.69 | 7.69 - 7.72 |
| Close: | 8.21 - 8.27 | 8.27 - 8.33 |
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
Fri, 26 Sep 2025
Arvinas (NASDAQ:ARVN) Trading 4.9% Higher - What's Next? - MarketBeat
Thu, 25 Sep 2025
Palumbo Wealth Management LLC Acquires Shares of 66,858 Arvinas, Inc. $ARVN - MarketBeat
Wed, 24 Sep 2025
Arvinas (NASDAQ:ARVN) Director Briggs Morrison Buys 30,000 Shares - MarketBeat
Wed, 24 Sep 2025
Clear Harbor Asset Management LLC Acquires New Holdings in Arvinas, Inc. $ARVN - MarketBeat
Tue, 23 Sep 2025
Arvinas, Inc. $ARVN Shares Sold by Goldman Sachs Group Inc. - MarketBeat
Wed, 17 Sep 2025
$100M Cost Savings: Arvinas Restructures, Out-Licenses Cancer Drug & Launches Major Share Buyback - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 73 (M) |
| Shares Float | 62 (M) |
| Held by Insiders | 6.8 (%) |
| Held by Institutions | 94.1 (%) |
| Shares Short | 8,570 (K) |
| Shares Short P.Month | 7,580 (K) |
| EPS | -1.01 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.31 |
| Profit Margin | -19.5 % |
| Operating Margin | -314.8 % |
| Return on Assets (ttm) | -6.8 % |
| Return on Equity (ttm) | -12 % |
| Qtrly Rev. Growth | -70.7 % |
| Gross Profit (p.s.) | 5.33 |
| Sales Per Share | 5.07 |
| EBITDA (p.s.) | -1.55 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -396 (M) |
| Levered Free Cash Flow | -182 (M) |
| PE Ratio | -8.19 |
| PEG Ratio | 0 |
| Price to Book value | 0.99 |
| Price to Sales | 1.62 |
| Price to Cash Flow | -1.54 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|